Feasibility of circulating tumor DNA testing in hepatocellular carcinoma | Zendy

Kabir Mody | Zendy; Pashtoon Murtaza Kasi | Zendy; Ju Dong Yang | Zendy; Phani Keerthi Surapaneni | Zendy; Ashton Ritter | Zendy; Ali Roberts | Zendy; Rebecca J. Nagy | Zendy; Mitesh J. Borad | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Feasibility of circulating tumor DNA testing in hepatocellular carcinoma

Author(s) -

Kabir Mody,

Pashtoon Murtaza Kasi,

Ju Dong Yang,

Phani Keerthi Surapaneni,

Ashton Ritter,

Ali Roberts,

Rebecca J. Nagy,

Mitesh J. Borad

Publication year - 2019

Publication title -

journal of gastrointestinal oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.084

H-Index - 39

eISSN - 2219-679X

pISSN - 2078-6891

DOI - 10.21037/jgo.2019.02.10

Subject(s) - medicine , hepatocellular carcinoma , indel , malignancy , oncology , cancer , genetic testing , gene , genetics , single nucleotide polymorphism , genotype , biology

Advancement of technologies enabling clinical assessment of circulating tumor DNA (ctDNA) are allowing for assessment of tumor specific genetic alterations in patients. This holds incredible promise for early detection of disease, serial monitoring of tumor heterogeneity, elucidation of therapeutic targets, and evaluation of treatment response and mechanisms of resistance. Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and is often diagnosed late, recurs commonly, and is often diagnosed based upon imaging features alone. A comprehensive evaluation of real-time evaluation of ctDNA in patients with HCC has thus far not been undertaken.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research